About
Pipeline
For patients & physicians
Investors
Contact us
About
About BerGenBio
Management Team
Board of Directors
Scientific Advisory Board
Partners
Pipeline
Pipeline overview
BEMCENTINIB | NSCLC
BEMCENTINIB | SRI
TILVESTAMAB (BGB149)
Publications
For patients & physicians
Investors
Share Information and Policies
Share Data
Largest Shareholders
Stock Exchange Notices
Analyst Coverage
News
Financial Reports
Presentations
Financial Calendar
Corporate Governance
General Meetings
Environmental social and governance - ESG
Investor Relations
Rights Issue 2023
Warrants
Contact us
Developing breakthrough AXL therapeutics to improve patients' lives
D
e
v
e
l
o
p
i
n
g
b
r
e
a
k
t
h
r
o
u
g
h
A
X
L
t
h
e
r
a
p
e
u
t
i
c
s
t
o
i
m
p
r
o
v
e
p
a
t
i
e
n
t
s
'
l
i
v
e
s
New: Learn about STK11m NSCLC
Learn About Us
Read more
Latest news
Read more
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
Recent News
10th October 2024
CEO Martin Olin steps down
Read more
10th October 2024
BerGenBio ASA: Minutes from Extraordinary General Meeting
Read more
7th October 2024
BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients
Read more
19th September 2024
BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
Read more
9th September 2024
BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference
Read more
21st August 2024
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
Read more
20th August 2024
BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer
Read more
15th August 2024
BerGenBio ASA: Registration of share capital reduction
Read more
13th August 2024
BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast
Read more
All news
